Venclexta Win Broadens AbbVie/Genentech CLL Positions
This article was originally published in Scrip
Executive Summary
AbbVie Inc. just won approval to market a drug to compete with, well, one of its own medicines, sort of.
You may also be interested in...
Venclexta Success In Second VIALE Study Sets Up Potential Full Approval In AML
Weeks after their first combo study with Venclexta in first-line AML failed, AbbVie and Genentech reported top-line data showing that the BCL-2 inhibitor plus azacitidine improved survival and remission rates.
After MURANO: Roche/AbbVie Map Venclexta's Expansion Past CLL
Sponsors expect that if Venclexta demonstrates compelling early data in new indications – like acute myeloid leukemia and multiple myeloma – the US FDA will be willing to help speed access for patients.
Verastem Sees Phase III Success With PIK3 Inhibitor Dropped By AbbVie
Duvelisib, licensed from Infinity in 2016, reduces risk of disease progression or death compared to Arzerra in a Phase III study in refractory CLL/SLL. Verastem hopes to file an NDA during the first half of 2018.